Intragel
Phase 3Small molecule
Intragel is one of 48 small molecule programs targeting Lateral Epicondylitis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Intragel
SShaare Zedek Medical Center
Phase 3
Epidiolex
Jazz PharmaceuticalsPreclinical
Toradol
RochePreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Paracetamol
GSKPreclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Lunesta
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intragel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShaare Zedek Medical Center